I.v. fentanyl decreases the clearance of midazolam

British Journal of Anaesthesia

Volumn 79, Issue 6, 1997, Pages 740-743

  Hase, I ^a   Oda, Y ^a   Tanaka, K ^a   Mizutani, K ^a   Nakamoto, T ^a   Asada, A ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Analgesics opioid, fentanyl; Enzymes, cytochrome P450; Hypnotics benzodiazepine, midazolam; Pharmacokinetics, fentanyl; Pharmacokinetics, midazolam

Indexed keywords

BENZODIAZEPINE; FENTANYL; ISOFLURANE; MIDAZOLAM; NARCOTIC ANALGESIC AGENT; NITROUS OXIDE;

ADOLESCENT; ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENERAL ANESTHESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030778221     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/79.6.740     Document Type: Article

References (25)

1. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clinical Pharmacology and Therapeutics 1981; 30: 653-661.
2. Persson P, Nilsson A, Hartvig P, Tamsen A. Pharmacokinetics of midazolam in total I.V. anaesthesia. British Journal of Anaesthesia 1987; 59: 548-556.
3. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology 1989; 36: 89-96.
4. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. British Journal of Anaesthesia 1994; 73: 658-661.
5. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics 1993; 53: 298-305.
6. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and Analgesia 1996; 82: 511-516.
7. Ahonen J, Olkkola KT, Salmenperä M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996; 85: 1246-1252.
8. Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthesia and Analgesia 1996; 82: 167-172.
9. Serlin MJ, Sibeon RG, Mossman S, Breckenridge AM, Williams JRB, Atwood JL, Willoughby JMT. Cimetidine: Interaction with oral anticoagulants in man. Lancet 1979; 2: 317-319.
10. Bailey PL, Pace NL, Ashburn MA, Moll JWB, East KA, Stanley TH. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology 1990; 73: 826-830.
11. Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI II, Miller RD, de Jong RH, Elashoff RM. Minimum alveolar concentrations (MAC) of isoflurane with and without nitrous oxide in patients of various ages. Anesthesiology 1975; 42: 197-200.
12. Puglisi CV, Pao J, Ferrara FJ, de Silva JAF. Determination of midazolam (Versed) and its metabolites in plasma by high-performance liquid chromatography. Journal of Chromatography 1985; 344: 199-209.
13. Michiels M, Hendriks R, Heykants J. A sensitive radioimmunoassay for fentanyl. European Journal of Clinical Pharmacology 1977; 12: 153-158.
14. Schüttler J, White PF. Optimization of the radioimmunoassays for measuring fentanyl and alfentanil in human serum. Anesthesiology 1984; 61: 315-320.
15. McClain DA, Hug CC jr. Intravenous fentanyl kinetics. Clinical Pharmacology and Therapeutics 1980; 28: 106-114.
16. Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. British Journal of Anaesthesia 1992; 69: 162-167.
17. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993; 79: 795-807.
18. Graham SG, Tateishi T, Guengerich FP, Wood AJJ, Wood M. Inhalational anesthetics inhibit CYP2E1 activity specifically. Anesthesiology 1995; 83: A342.
19. Murayama N, Shimada M, Yamazoe Y, Sogawa K, Nakayama K, Fujii-Kuriyama Y, Kato R. Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. Archives of Biochemistry and Biophysics 1996; 328: 184-192.
20. Nakamoto T, Oda Y, Imaoka S, Funae Y, Fujimori M. Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: Correlation with P450 isoform levels. Drug Metabolism and Disposition 1997; 25: 296-300.
21. Hughes RL, Mathie RT, Fitch W, Campbell D. Liver blood flow and oxygen consumption during hypocapnia and IPPV in the greyhound. Journal of Applied Physiology 1979; 47: 290-295.
22. Gelman SI. Disturbances in hepatic blood flow during anesthesia and surgery. Archives of Surgery 1976; 111: 881-883.
23. 2O anesthesia. Anesthesia and Analgesia 1990; 71: 349-353.
24. Gelman S, Dillard E, Bradley EL jr. Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl. Anesthesia and Analgesia 1987; 66: 936-943.
25. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 1996; 59: 491-502.